ES2000428T3 - Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente. - Google Patents

Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.

Info

Publication number
ES2000428T3
ES2000428T3 ES198787100461T ES87100461T ES2000428T3 ES 2000428 T3 ES2000428 T3 ES 2000428T3 ES 198787100461 T ES198787100461 T ES 198787100461T ES 87100461 T ES87100461 T ES 87100461T ES 2000428 T3 ES2000428 T3 ES 2000428T3
Authority
ES
Spain
Prior art keywords
alzheimer
disease
medication
procedure
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787100461T
Other languages
English (en)
Spanish (es)
Other versions
ES2000428A4 (es
ES2000428T9 (es
Inventor
Bonnie M. Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synaptech Inc
Original Assignee
Synaptech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25227312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2000428(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synaptech Inc filed Critical Synaptech Inc
Publication of ES2000428A4 publication Critical patent/ES2000428A4/es
Application granted granted Critical
Publication of ES2000428T3 publication Critical patent/ES2000428T3/es
Anticipated expiration legal-status Critical
Publication of ES2000428T9 publication Critical patent/ES2000428T9/es
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
ES198787100461T 1986-01-15 1987-01-15 Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente. Expired - Lifetime ES2000428T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US819141 1986-01-15
US06/819,141 US4663318A (en) 1986-01-15 1986-01-15 Method of treating Alzheimer's disease

Publications (3)

Publication Number Publication Date
ES2000428A4 ES2000428A4 (es) 1988-03-01
ES2000428T3 true ES2000428T3 (es) 1993-10-01
ES2000428T9 ES2000428T9 (es) 2013-08-14

Family

ID=25227312

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787100461T Expired - Lifetime ES2000428T3 (es) 1986-01-15 1987-01-15 Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.

Country Status (10)

Country Link
US (1) US4663318A (enExample)
EP (1) EP0236684B1 (enExample)
JP (1) JPH08778B2 (enExample)
AT (1) ATE76294T1 (enExample)
AU (1) AU593051B2 (enExample)
DE (3) DE10199020I2 (enExample)
ES (1) ES2000428T3 (enExample)
GR (2) GR880300077T1 (enExample)
LU (1) LU90710I2 (enExample)
NL (1) NL300140I2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
JP2755403B2 (ja) * 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
EP0584185B1 (en) * 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
NZ294191A (en) * 1994-10-21 1998-10-28 Waldheim Pharmazeutika Gmbh Process for preparing 4a,5,9,10,11,12-hexahydro-6h-benzofuro[3a,3,2-ef][2]benzazepine derivatives and intermediates thereof
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
KR100437105B1 (ko) * 1998-12-24 2004-06-23 얀센 파마슈티카 엔.브이. 방출 조절형 갈란타민 조성물
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
US6426097B2 (en) 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
EP1261345B1 (en) * 2000-01-28 2005-06-15 Tricia Grose Herbal supplement for cognitive related impairment due to estrogen loss
PL202463B1 (pl) 2000-03-31 2009-06-30 Sanochemia Pharmazeutika Ag Pochodne galantaminy, sposób ich wytwarzania, środek leczniczy zawierajacy te pochodne, zastosowanie pochodnej galantaminy do wytwarzania środków leczniczych, sposób wytwarzania środków leczniczych oraz sposób oddzielania (+)- i (-)-izomerów
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CA2310990A1 (en) 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
WO2003105830A1 (ja) 2002-06-14 2003-12-24 富山化学工業株式会社 脳機能を改善する医薬組成物および脳機能を改善するための方法
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2003274353B2 (en) * 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
CA2527114A1 (en) * 2003-05-30 2004-12-16 Microbia, Inc. Methods for the protection of memory and cognition
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
KR100764330B1 (ko) * 2003-07-25 2007-10-05 에프. 호프만-라 로슈 아게 급성 및/또는 만성 신경학적 장애의 치료를 위한ｍＧｌｕＲ2 길항제 및 ＡＣｈＥ 억제제의 조합물
WO2005042762A2 (en) * 2003-10-28 2005-05-12 Genaissance Pharmaceuticals, Inc. Lrpap1 genetic markers associated with galantamine response
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
EP1718291A1 (en) * 2004-02-19 2006-11-08 Novartis AG Use of cholinesterase inhibitors for treating vascular depression
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
US20050267077A1 (en) * 2004-05-14 2005-12-01 Johns Hopkins University Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
BRPI0718437A2 (pt) 2006-10-27 2013-11-19 Medivation Neurology Inc Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
EP4088717A1 (en) * 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
ES2746480T3 (es) 2009-09-18 2020-03-06 Chase Pharmaceuticals Corp Combinación para tratar demencia de tipo Alzheimer
EP2503996A2 (en) 2009-11-26 2012-10-03 USV Limited Controlled release pharmaceutical compositions of galantamine
US20110212928A1 (en) 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
KR20200065113A (ko) 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam

Also Published As

Publication number Publication date
LU90710I2 (fr) 2001-03-05
NL300140I2 (nl) 2004-04-01
DE10199020I1 (de) 2001-05-23
DE236684T1 (de) 1988-04-28
ES2000428A4 (es) 1988-03-01
GR880300077T1 (en) 1988-10-21
NL300140I1 (nl) 2004-02-02
ES2000428T9 (es) 2013-08-14
JPS62215527A (ja) 1987-09-22
EP0236684A3 (en) 1988-12-14
DE10199020I2 (de) 2004-05-06
GR3005447T3 (enExample) 1993-05-24
EP0236684B1 (en) 1992-05-20
EP0236684A2 (en) 1987-09-16
AU593051B2 (en) 1990-02-01
US4663318A (en) 1987-05-05
DE3779149D1 (de) 1992-06-25
ATE76294T1 (de) 1992-06-15
JPH08778B2 (ja) 1996-01-10
AU6760987A (en) 1987-07-16

Similar Documents

Publication Publication Date Title
ES2000428A4 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
NO871549D0 (no) Medikament for behandling av oeyenbetennelser.
NO951592L (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
ES554273A0 (es) Un procedimiento para producir un dispositivo medico esterilizado por radiacion particularmente adecuado para el tratamiento de la sangre.
ATE50493T1 (de) Ibuprofen enthaltendes arzneimittel.
PT97552A (pt) Processo para a preparacao de formas de dosagem para administracao de farmacos para o tratamento da doenca de parkison
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
PT88138A (pt) Processo para a producao de uma forma de administracao ou de dosagem para substancias medicinais activas por meio de um processo de impressao
ATA91797A (de) Eine das vwf-propeptid enthaltende pharmazeutische präparation
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
IT8722512A0 (it) Dispositivo per l&#39; irradiazione di raggi di luce destinato a trattamenti medici.
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
ES2081279T3 (es) Utilizacion de 15-desoxiespergualina como medicamento.
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
SE9101341D0 (sv) New medicinal use
IT1224250B (it) Associzione del depiprazolo con la morfina
ZA885625B (en) Therapeutic agents containing enantiomers of propafenone
SU540063A1 (ru) Гидроцилиндр одностороннего действи
ATE84418T1 (de) 2,6-diamino-3-phenyl-azo-pyridin enthaltendes tier- und humanarzneimittel mit antiviraler und antitumoraler aktivitaet.
PH30028A (en) Treatment of anxiety in benzodiazepine withdrawn patients
UA16000A1 (uk) Спосіб лікуваhhя гіпотрофії поросят

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 236684

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: GALANTAMINA (REMINYL)

Spc suppl protection certif: C200100009

Filing date: 20010201

SPCG Supplementary protection certificate granted

Free format text: GALANTAMINA (REMINYL)

Spc suppl protection certif: C200100009

Filing date: 20010201

Expiry date: 20120115

Effective date: 20031211